In view of the tumor immune microenvironment, the association and feasibility of radiomics-based biomarkers to tumor-infiltrating immune cell (33–36), the response of immunotherapy (37–41), and PD-L1/PD-L2 expression level (42–44) have also been investigated. The gene discussed is PDCD1LG2; the disease is neoplasm.